GUERBET (EPA:GBT) | Finanzwire

BRIEF

published on 03/20/2024 at 17:50, 8 months 2 days ago

Guerbet Announces Solid Growth and Improved Profitability in 2023 Full-Year Results

Financial Results Profitability Guerbet Healthcare Imaging 2023 Growth
PRESS RELEASE

published on 03/20/2024 at 17:45, 8 months 2 days ago

Guerbet: 2023 full-year results.
Guerbet publishes solid 2023 full-year results with revenue growth of 5.9% at CER and EBITDA margin exceeding target. Confirms outlook for 2024 with revenue growth > 8% and higher profitability

Revenue Growth 2024 Outlook EBITDA Margin Guerbet 2023 Full-year Results
BRIEF

published on 03/11/2024 at 08:05, 8 months 12 days ago

Guerbet announces key appointments to boost its long-term strategy

Innovation Appointments Guerbet Medical Imaging Long-term Strategy
PRESS RELEASE

published on 03/11/2024 at 08:00, 8 months 12 days ago

Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.
Guerbet announces the appointment of Christine Allard as SVP Public Affairs and Corporate Communications, and Eva Ohlsson as SVP Human Resources, to strengthen its Executive Committee for long-term goals

Appointments Executive Committee Guerbet Christine Allard Eva Ohlsson
PRESS RELEASE

published on 02/08/2024 at 17:45, 9 months 14 days ago

Guerbet: 2023 revenue
Guerbet reports 2023 revenue growth of 6.4% at constant exchange rates, with an anticipated 2024 revenue growth of over 8%. Restated EBITDA margin exceeds initial 11% target, while 2024 profitability target remains at 14.4%

2024 Guidance Guerbet Medical Imaging 2023 Revenue Restated EBITDA Margin
PRESS RELEASE

published on 01/30/2024 at 17:45, 9 months 23 days ago

Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.
Guerbet announces the passing of Michel Guerbet, son of the founder, and company director for over 30 years. The Group pays tribute to his exceptional leadership and significant contributions to the company's development

Guerbet Michel Guerbet Company Director Medical Imaging Pharmaceutical Products
PRESS RELEASE

published on 01/11/2023 at 18:23, 1 year 10 months ago

Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions

Published on 11/22/2024 at 23:55, 10 hours 31 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 10 hours 56 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 11 hours 21 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 11 hours 21 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 11 hours 56 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 16 hours 12 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 16 hours 26 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 16 hours 33 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 17 hours 31 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 18 hours 26 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 19 hours 51 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 15 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 16 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 16 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News